Agreement one time fee.

No definition available.

Name:	ibrx_AgreementOneTimeFee
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Annual payments for support of reasearch and development activities.

+ References

No definition available.

+ Details

Name:	ibrx_AnnualPaymentsForSupportOfReasearchAndDevelopmentActivities
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Estimated unpaid research and development expense amount.

+ References

No definition available.

+ Details

Name:	ibrx_EstimatedUnpaidResearchAndDevelopmentExpenseAmount
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement term.

+ References

No definition available.

+ Details

Name:	ibrx_LicenseAgreementTerm
Namespace Prefix:	ibrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License agreement termination notice period.

+ References

No definition available.

+ Details

Name:	ibrx_LicenseAgreementTerminationNoticePeriod
Namespace Prefix:	ibrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License fee amount for first two years of the agreement.

+ References

No definition available.

+ Details

Name:	ibrx_LicenseFeeAmountForFirstTwoYearsOfTheAgreement
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Licensing agreement.

+ References

No definition available.

+ Details

Name:	ibrx_LicensingAgreementLineItems
Namespace Prefix:	ibrx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone payment amount.

+ References

No definition available.

+ Details

Name:	ibrx_MilestonePaymentAmount
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Minimum annual research and development payment.

+ References

No definition available.

+ Details

Name:	ibrx_MinimumAnnualResearchAndDevelopmentPayment
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Minimum annual royalty payment.

+ References

No definition available.

+ Details

Name:	ibrx_MinimumAnnualRoyaltyPayment
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Minimum sales milestone of license for first year.

+ References

No definition available.

+ Details

Name:	ibrx_MinimumSalesMilestoneOfLicenseForFirstYear
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of milestone payments payable in cash.

+ References

No definition available.

+ Details

Name:	ibrx_PercentageOfMilestonePaymentsPayableInCash
Namespace Prefix:	ibrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of milestone payments payable in shares.

+ References

No definition available.

+ Details

Name:	ibrx_PercentageOfMilestonePaymentsPayableInShares
Namespace Prefix:	ibrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Period of license agreement.

+ References

No definition available.

+ Details

Name:	ibrx_PeriodOfLicenseAgreement
Namespace Prefix:	ibrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of agreement.

+ References

No definition available.

+ Details

Name:	ibrx_TermOfAgreement
Namespace Prefix:	ibrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of agreement commencing date.

+ References

No definition available.

+ Details

Name:	ibrx_TermOfAgreementCommencingDate
Namespace Prefix:	ibrx_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of agreement expired date.

+ References

No definition available.

+ Details

Name:	ibrx_TermOfAgreementExpiredDate
Namespace Prefix:	ibrx_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Total milestone payment amount.

+ References

No definition available.

+ Details

Name:	ibrx_TotalMilestonePaymentAmount
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Total sales milestone payment amount of license.

+ References

No definition available.

+ Details

Name:	ibrx_TotalSalesMilestonePaymentAmountOfLicense
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront cash payment.

+ References

No definition available.

+ Details

Name:	ibrx_UpfrontCashPayment
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.

+ References

No definition available.

+ Details

Name:	us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DueToRelatedPartiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_OtherCommitmentsAxis=ibrx_RushUniversityMedicalCenterLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=ibrx_ViractaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibrx_CooperativeResearchAndDevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibrx_GlobeimmuneExclusiveLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibrx_CancerTherapeuticsLaboratoriesIncexclusiveLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibrx_CytrxCorporationexclusiveLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibrx_PrecigenLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_INDFilingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_PhaseTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_PhaseThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_CommercialSaleRelatedToLicensedProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=ibrx_AccruedExpensesAndOtherLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibrx_IosbioLtdExclusiveLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ibrx_MilestoneAxis=ibrx_ClinicalAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ibrx_MilestoneAxis=ibrx_RegulatoryApprovalsAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ibrx_AgencyAxis=ibrx_NationalCancerInstituteOfTheNationalInstitutesOfHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibrx_AmendedCooperativeResearchAndDevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Additional Information (Detail) - USD ($)				1 Months Ended	12 Months Ended
	May 31, 2017	Feb. 28, 2010	Dec. 31, 2004	Jan. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Licensing Agreement [Line Items]
Payments for research and development expense					$ 139,507,000	$ 111,997,000
Due to related parties					$ 14,838,000	11,393,000
Rush University Medical Center License Agreement
Licensing Agreement [Line Items]
Period of license agreement			12 days
Minimum annual royalty payment			$ 25,000
Payments in license agreement			2,500,000
Minimum sales milestone of license for first year			$ 300,000
Viracta Therapeutics, Inc.
Licensing Agreement [Line Items]
License agreement termination notice period	90 days
Viracta Therapeutics, Inc. \| Minimum
Licensing Agreement [Line Items]
Milestone Payment Amount	$ 10,000,000.0
Viracta Therapeutics, Inc. \| Maximum
Licensing Agreement [Line Items]
Milestone Payment Amount	$ 25,000,000.0
Cooperative Research And Development Agreement
Licensing Agreement [Line Items]
Term of agreement commencing date					Feb. 20, 2018
Term of agreement expired date					Feb. 20, 2023
Term of agreement					5 years
GlobeImmune Exclusive License Agreement
Licensing Agreement [Line Items]
License fee amount for first two years of the agreement				$ 1,200,000
Total sale milestone payments amount of license				240,000,000.0
License agreement termination notice period					60 days
Cancer Therapeutics Laboratories, Inc. Exclusive License Agreement
Licensing Agreement [Line Items]
Upfront cash payment					$ 5,000,000.0
Percentage of milestone payments payable in cash					15.00%
Percentage Of Milestone Payments Payable In Shares					85.00%
Due to related parties					$ 0	0
License agreement termination notice period					60 days
CytRx CorporationExclusive License Agreement
Licensing Agreement [Line Items]
Due to related parties					$ 0	0
License agreement termination notice period					12 months
Precigen License Agreement
Licensing Agreement [Line Items]
Milestone Payment Amount					$ 0	0
License agreement term (years)		17 years
Agreement one time fee		$ 400,000
Milestone payments to be received					0	0
Precigen License Agreement \| First IND Filing
Licensing Agreement [Line Items]
Milestone Payment Amount		100,000
Precigen License Agreement \| First Phase II Clinical Trial
Licensing Agreement [Line Items]
Milestone Payment Amount		100,000
Precigen License Agreement \| First Phase III Clinical Trial
Licensing Agreement [Line Items]
Milestone Payment Amount		400,000
Precigen License Agreement \| Commercial Sale Related to Licensed Products
Licensing Agreement [Line Items]
Milestone Payment Amount		$ 500,000
Accrued Expenses and Other Liabilities \| IosBio Ltd. Exclusive License Agreement
Licensing Agreement [Line Items]
Accrued payable of reimbursable costs related to clinical trial activities					500,000
Clinical and Regulatory Milestones \| GlobeImmune Exclusive License Agreement
Licensing Agreement [Line Items]
Milestone Payment Amount				$ 345,000,000.0
Clinical and Regulatory Milestones \| Cancer Therapeutics Laboratories, Inc. Exclusive License Agreement
Licensing Agreement [Line Items]
Total Milestone Payment Amount					10,000,000.0
Regulatory Approvals and Commercial Milestones \| CytRx CorporationExclusive License Agreement
Licensing Agreement [Line Items]
Milestone payments to be received					346,000,000.0
National Cancer Institute \| Cooperative Research And Development Agreement
Licensing Agreement [Line Items]
Annual payments for support of reasearch and development activities					600,000
Payments for research and development expense					600,000	600,000
National Cancer Institute \| Amended Cooperative Research and Development Agreement
Licensing Agreement [Line Items]
Minimum annual research and development payment					200,000
Estimated unpaid research and development expense amount					$ 600,000	$ 300,000
License agreement termination notice period					60 days